Piyasa açık· · CAD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, today announced that Luc Mainville will be leaving his position as Chief Financial Officer of the Corporation, effective immediately.
LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the second quarter of its 2026 fiscal year, ended June 30, 2026 ("Q2-26" and "YTD 2026"). All amounts are presented in millions of Canadian dollars.
LSL PHARMA GROUP INC. (TSXV: LSL) (The "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to provide an update regarding the remediation plan initiated by Steri-Med Pharma Inc. ("Steri-Med"), as previously announced in the Corporation's news release dated April 30, 2026.
LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), a Canadian integrated pharmaceutical company, today announced the voting results of its annual general and special meeting of shareholders held in a hybrid format on June 19, 2026 (the "Meeting").
LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, is pleased to announce the signing of a multi-year supply agreement for the distribution of Erythromycin manufactured by its subsidiary Steri-Med Pharma Inc. ("Steri-Med") to hospitals located outside the Province of Québec. In addition, SterisporinTM, our over-the-counter ophthalmic ointment product, also manufactured by Steri-Med, has recently been listed by the two largest Can
LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2026 ("Q1-26"). All amounts are presented in millions ("M") of Canadian dollars.
LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025 ("Q4-25" and "FY-25"). All amounts are presented in millions ("M") of Canadian dollars.
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.